Advertisement
Organisation › Details
Biocartis (Group)
Biocartis aims to improve healthcare outcomes by enabling the practice of personalized medicine anywhere, anytime. Biocartis' ambition is to establish a new gold standard in diagnostic testing. Biocartis provides innovative research and diagnostic systems with multiplex detection and simplified workflows which require less hands-on time and minimize sample requirements (especially for tumor biopsies). Additionally, Biocartis develops assays which have high clinical utility and compelling health economic value. Oncology is the primary focus of Biocartis as this is one of the greatest unmet needs for personalized medicine. Biocartis is well suited to address the growing need for individualized diagnosis and treatment of cancer patients. Biocartis is a rapidly growing company; to date Biocartis staff includes over 140 people. The company has raised in total EUR 125 million in equity. *
Start | 2007-01-01 established | |
Industry | molecular diagnostics | |
Industry 2 | cancer test | |
Person | Verrelst, Herman (Biocartis 202304– Board Chair before CEO before Agilent + Cartagenia + Medicim + Data4s) | |
Street | 11 B3 Gen. De Wittelaan | |
City | 2800 Mechelen | |
Tel | +32-15-632-600 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | D: 101 to 500 (2022-12-31) |
Currency | EUR | |
Annual sales | 57,481,000 (revenue, total, consolidated (2022) 2022-12-31) | |
Profit | -65,381,000 (2022-12-31) | |
Cash | 26,125,000 (2022-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Biocartis (Group)
- [1] Biocartis Group N.V.. (4/4/23). "Press Release: Biocartis and APIS Assay Technologies Sign Collaboration to Develop and Commercialise a Breast Cancer Subtyping Test on the Idylla Platform". Mechelen....
- [2] NeoGenomics, Inc.. (5/9/22). "Press Release: NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary". Ft. Myers, FL....
- [3] Biocartis Group N.V.. (11/27/17). "Press Release: Biocartis Launches CE-marked IVD RAS Liquid Biopsy Tests Developed under Partnership with Merck KGaA, Darmstadt, Germany". Mechelen....
- [4] Biocartis Group N.V.. (11/16/17). "Press Release: Biocartis Q3 2017 Business Update". Mechelen....
- [5] Biocartis Group N.V.. (5/18/17). "Press Release: Study Demonstrating High Performance of Idylla Liquid Biopsy RAS Tests to be presented at ASCO Annual Meeting". Mechelen....
- [6] Biocartis Group N.V.. (4/4/17). "Press Release: Biocartis Establishes US Subsidiary and Appoints US General Manager". Mechelen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top